Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact, and developing methods for matching the right treatment to the right patient. So far, a deep understanding of the biology underlying diseases and health has been hindered by the shortcomings of existing tools for protein characterisation.
Founded in 2013, UK-based biotech startup Fluidic Analytics has raised €27 million for its platform that characterises proteins and their behaviour.
Developed at the University of Cambridge, Fluidic Analytics’ platform was designed to give deep insights into the way that proteins fold, aggregate and interact by characterising them in solution – exactly as they exist in the body. Its products have the potential to help researchers understand the mechanisms underlying conditions like Alzheimer’s disease, help pharmaceutical companies develop more effective drugs, and to help patients gain access to more accurate diagnostics.
The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners. The company will use the funding to continue the commercial roll-out of its lab-tools pipeline, and to further develop clinical applications of its technology.
Andrew Lynn, CEO of Fluidic Analytics, said: “This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market. It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world. We are delighted to be working with investors who share our vision of helping people everywhere make better decisions about how diseases are diagnosed, treatments are developed, and personal well-being is maintained.”
Tim Rea, Investor at BGF, commented: “The team at Fluidic Analytics have built a potentially life-changing technology and brought their idea from concept to production in an incredibly short time. The market for pharmaceutical tools and technology is thriving and Fluidic Analytics has created products for which there is growing demand. We’re excited to be supporting the team as they scale up and take advantage of the significant opportunity to develop this critical technology further.”